12:30 AM EDT, 09/30/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We raise our 12-month price target by $35 to $350, 20x our FY 26 (Sep.) EPS estimate (down $0.01 to $17.46; FY 25 estimate up $0.02 to $15.94), a premium to COR's three-year historical forward average of 14.9x to reflect our view of a supportive environment for pharma distributors, as well as some incremental benefits from relatively lower tariff, regulatory, and recession risks relative to other health care sub-industries, in our view. Our target multiple is above peer Cardinal Health (CAH 155****) and below peer McKesson (MCK 762****). We are encouraged by COR's commentary in recent investor conferences, in which management reiterated strong trends for U.S. pharma sales and profitability growth, including contributions from specialty drugs. COR also looks positively on higher growth potential from recent acquisitions outside of the core pharma distribution business, such as the $4.4B investment for 85% of RCA, while management sees its animal health distribution operations as gaining market share.